Intrathecal betamethasone for cancer pain in the lower half of the body: A study of its analgesic efficacy and safety

British Journal of Anaesthesia

Volumn 98, Issue 3, 2007, Pages 385-389

  Taguchi, H ^a   Oishi, K ^a   Sakamoto, S ^a   Shingu, K ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Analgesic techniques, subarachnoid; Analgesics anti inflammatory, steroid; Cancer; Pain; Toxicity, neurotoxicity

Indexed keywords

BETAMETHASONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ARTICLE; BACKACHE; BLADDER DYSFUNCTION; CANCER PAIN; CLINICAL ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GAIT DISORDER; HUMAN; LOW BACK PAIN; MALE; MOTOR DYSFUNCTION; NEUROTOXICITY; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; RECTUM DISEASE; SCORING SYSTEM; SENSORY DYSFUNCTION; SPINE METASTASIS; VISUAL ANALOG SCALE; WEAKNESS; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRACTABLE PAIN; INTRASPINAL DRUG ADMINISTRATION; MIDDLE AGED; NEOPLASM;

AGED; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, SPINAL; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN MEASUREMENT; PAIN, INTRACTABLE;

EID: 34247874628     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael363     Document Type: Article

References (28)

1. Portenoy RK, Lesage P. Manegement of cancer pain. Lancet 1999; 353: 1695-700
2. Schell HW. Adrenal corticosteroid therapy in far advanced cancer. Geriatrics 1972; 27: 131-41
3. Cherny NI, Portenoy RK. Practical issues in the management of cancer pain. Anesthesiology 1999: 91: 1937-41
4. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs 1994; 47: 28-45
5. Ahlgren SC, Wang JF, Levine JD. C-fiber mechanical stimulus-response functions are different in inflammatory versus neuropathic hyperalgesia in the rat. Neuroscience 1997; 76: 285-90
6. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol 2005; 192: 444-62
7. Rowbotham MC. Mechanisms of neuropathic pain and their implications for the design of clinical trials. Neurology 2005; 65: 66-73
8. Nelson DA. Intraspinal therapy using methylprednisolone acetate. Twenty-three years of clinical controversy. Spine 1993: 18: 278-86
9. Taguchi H, Shingu K, Okuda H, et al. Analgesia for pelvic and perineal cancer pain by intrathecal steroid injection. Acta Anaesth Scand 2002; 46: 190-3
10. Roche J. Steroid-induced arachnoiditis. Med J Aust 1984; 140 281-4
11. Nelson DA, Landau WM. Intrathecal steroids. history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports. J Neurol Neurosurg Psychiatry 2001; 70: 433-43
12. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methyl-prednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343: 1514-9
13. Langmayr JJ, Obwegeser AA, Schwarz AB, et al. Intrathecal steroids to reduce pain after lumbar disc surgery: A double-blind, placebo-controlled prospective study. Pain 1995; 62: 357-61
14. Latham JM, Fraser RD, Moore RJ, et al. The pathologic effects of intrathecal betamethasone. Spine 1997, 22: 1558-62
15. Abram SE, Marsala M, Yaksh TL. Analgesic and neurotoxic effects of intrathecal corticosteroids in rats. Anesthesiology 1994; 81 1198-205
16. Hodgson PS, Neal JM, Pollock JE, et al. The neurotoxicity of drugs given intrathecally (spinal). Anesth Analg 1999; 88: 797-809
17. Feroci G, Fini A. Study of the antioxidant effect of the selenium and sulfur compounds. J Trace Elem Med Biol 1998; 12: 96-100
18. Gissen AJ, Datta S, Lambert D. The chloroprocaine controversy. Is chloroprocaine neurotoxic? Reg Anesth 1984; 9: 135-45
19. Taniguchi M, Bollen A, Drasner K. Sodium bisulfite: Scapegoat for chloroprocaine neurotoxicity? Anesthesiology 2004; 100: 85-91
20. Takeda K, Sawamura S, Sekiyama H, et al. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. Anesthesiology 2004; 100: 1249-57
21. Hains BC, Waxman SG. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 2006; 26 4308-17
22. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005; 14: 166-74
23. Cunningham FM, Lees P. Advances in anti-inflammatory therapy. Br Vet J 1994; 150: 115-134
24. Jusko WJ. Receptor-mediated pharmacodynamics of cortico-steroids. Prog Clin Biol Res 1994; 387: 261-70
25. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997; 59: 365-93
26. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999; 79: 1-13
27. Ferrer-Brechner T. Anesthetic techniques for the management of cancer pain. Cancer 1989; 63: 2343-7
28. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Safety 1994: 11: 163-78